Huntington’s Disease: The New Gene Therapy That Sufferers Cannot Afford

May 16, 2016

(The Guardian) – Advanced therapeutics for rare, so-called orphan diseases will be expensive. An extreme example is the price of Glybera, developed by the Dutch company Uniqure to combat a rare disease that causes pancreatitis, which was set at $1m per patient. Ionis-HTTRx will not be as expensive as Glybera – nowhere near – but it will still be so expensive that only governments and insurance companies will be able to afford it. Glybera is administered only once, whereas Ionis-HTTRx would be taken many times, meaning the drug company could recoup costs and make profit over a patient’s lifetime rather than in one lump sum.

The views, opinions and positions expressed by these authors and blogs are theirs and do not necessarily represent that of the Bioethics Research Library and Kennedy Institute of Ethics or Georgetown University.